180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions
180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions. Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021 The company is to be acquired by a SPAC (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF Pioneering biotech company, 180 Life Sciences Corp. is bringing hope to sufferers of Dupuytren’s Disease and other inflammatory conditions caused by an impaired immune system. Currently, the company has three major programs…